Repatha (Evolocumab) What to Expect: A Week-by-Week Guide to Your First Month

How Evolocumab Works Before You Even Notice a Change

Evolocumab blocks PCSK9, a protein that degrades LDL receptors on liver cells. With fewer functional receptors, the liver clears less LDL from the blood. Evolocumab prevents that degradation, restoring receptor activity and driving LDL out of circulation rapidly. The mechanism is distinct from statins, which reduce cholesterol synthesis, making the two drug classes highly complementary.

The FDA approved evolocumab on August 27, 2015, for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering beyond diet and maximally tolerated statin therapy [1].

The PCSK9 Pathway in Plain Language

PCSK9 binds to LDL receptors on hepatocytes, tagging them for destruction inside the cell. Evolocumab is a fully human IgG2 monoclonal antibody that binds circulating PCSK9 with high affinity, preventing the PCSK9-receptor complex from forming [2]. The result: more intact LDL receptors cycle back to the cell surface, and LDL plasma concentrations drop sharply within hours.

Why Baseline LDL Matters for Expectations

Patients with HeFH often start with LDL above 190 mg/dL despite statin use [3]. The absolute drop evolocumab produces scales with baseline LDL, so a patient at 180 mg/dL might fall to roughly 65 mg/dL, while a patient already at 100 mg/dL might reach 35 mg/dL. The American College of Cardiology and American Heart Association 2018 guideline recommends a target of <70 mg/dL for very high-risk ASCVD patients [4].

Days 1 Through 3: The Injection and the Immediate Hours After

The first injection is the most uncertain moment for most patients. It should not be.

Evolocumab comes in two self-injection devices: a single-use prefilled autoinjector (SureClick) and a prefilled syringe. The 140 mg dose uses one device; the 420 mg monthly dose requires three consecutive injections within 30 minutes [5]. Remove the device from the refrigerator 30 minutes before use to reduce injection-site stinging.

Choosing Your Injection Site

The FDA-approved prescribing information specifies the abdomen, thigh, or upper arm as acceptable injection sites [5]. Rotate sites with each dose. Avoid skin that is bruised, tender, or affected by psoriasis. Alcohol-swab the site and allow it to dry fully before inserting the needle.

What Happens Inside Your Body on Day 1

Subcutaneous evolocumab reaches peak plasma concentration (Tmax) in approximately 3 to 4 days, but PCSK9 inhibition begins within hours of injection [2]. A 2012 pharmacodynamic study published in the Journal of Clinical Investigation showed that a single subcutaneous dose of 1 mg/kg evolocumab reduced free PCSK9 by more than 90 percent within 24 hours and produced measurable LDL reduction in the same window [6]. You will not feel this change. LDL reduction is biochemical, not symptomatic.

Common Day-1 and Day-2 Side Effects

Injection-site reactions, including redness, bruising, pain, and swelling, occur in approximately 3.1 percent of patients in the pooled phase 3 program [5]. These reactions are almost always mild and resolve within 3 to 7 days. Nasopharyngitis (roughly 11 percent incidence in FOURIER) and upper respiratory tract infections were the most common non-injection-site adverse events, though the rates were not meaningfully different from placebo [7].

Week 1: Watching for Early Tolerability Signals

By day 5 to 7, evolocumab plasma levels are approaching their peak. LDL is already falling, even though you will not have lab confirmation yet. Your primary job this week is to monitor tolerability, not efficacy.

Injection-Site Reactions: When to Watch Closely

A small area of redness or a pea-sized lump at the injection site is expected and benign. Contact your prescriber if redness spreads beyond 3 centimeters, if you develop hives, or if you experience difficulty breathing, which could indicate an allergic reaction. Anaphylaxis has been reported with evolocumab; the prescribing information recommends discontinuing the drug and treating appropriately if this occurs [5].

Muscle Symptoms and Statin Context

Many patients starting evolocumab are already on a statin. Any new muscle aching in week 1 is more likely attributable to the background statin than to evolocumab. The FOURIER trial (N=27,564) did not find a statistically significant increase in myalgia or myopathy with evolocumab versus placebo (3.5 percent vs. 3.2 percent, P=0.08) [7]. If myalgia worsens substantially, contact your prescriber to assess creatine kinase.

Neurocognitive Symptoms: The Real-World Picture

Post-marketing reports raised concern about cognitive effects with PCSK9 inhibitors. The FDA issued a label update in 2017 requesting postmarket studies [8]. The dedicated EBBINGHAUS trial (N=1,204), published in the New England Journal of Medicine in 2017, found no significant difference between evolocumab and placebo in the Cambridge Neuropsychological Test Automated Battery (CANTAB) composite score at 19 months (P=0.39) [9]. New cognitive symptoms in week 1 are almost certainly unrelated to evolocumab.

Week 2: Your LDL Has Already Moved

By week 2, most patients on 140 mg every two weeks are at or near peak LDL reduction. The key phase 2 MENDEL study (N=614) showed that the maximum LDL lowering from a 140 mg dose occurred at approximately day 14 and was maintained until the next injection [10].

Expected LDL Numbers at Week 2

The LAPLACE-2 trial (N=1,896) tested evolocumab across multiple statin backgrounds and doses [11]. Patients on moderate-intensity statin plus evolocumab 140 mg Q2W achieved a mean LDL reduction of 63.2 percent from baseline at week 12, with the pharmacokinetic nadir of LDL occurring around day 14 of each dosing cycle. You may have a lipid panel ordered at this point; some prescribers prefer to check at week 4 or 8 for a steadier read.

Why LDL May Drift Slightly Higher Before Dose 2

Evolocumab has a half-life of approximately 11 to 17 days [2]. As the first dose is cleared, free PCSK9 rises again and LDL begins to creep upward. This is pharmacokinetically expected. The trough LDL (just before the next dose) is still substantially below baseline in virtually all patients, but some individuals notice that a lipid panel drawn at day 13 looks slightly less impressive than one drawn at day 7. This does not indicate treatment failure.

Week 3: Dose 2 (If on the Every-Two-Week Schedule)

Patients on the 140 mg Q2W regimen administer their second injection at day 14 (plus or minus a day or two). The second dose re-suppresses PCSK9 before the LDL rebound becomes clinically meaningful.

Adherence at the Second Dose

Real-world adherence data are worth examining. A 2020 analysis of US commercial claims (N=9,364 patients on PCSK9 inhibitors) found that 12-month persistence was only 44 percent, and the most common reason for discontinuation was cost or insurance issues rather than adverse effects [12]. Setting up auto-refill, using the Amgen PCSK9 copay program where eligible, and placing a calendar reminder for injection day 14 significantly reduces the chance of missing a dose.

Injection Rotation and Site Selection at Dose 2

Rotate away from the site used for dose 1. If you injected into the left thigh, use the right thigh, abdomen, or upper arm for dose 2 [5]. Document injection sites in a simple log or phone note; this habit prevents repeated use of the same small area, which can increase bruising.

Week 4: The First Labs and What They Mean

Most prescribers order a fasting lipid panel at 4 to 8 weeks after starting evolocumab. Week 4 represents approximately two full dosing cycles on the Q2W schedule and is a reasonable time to assess response.

Interpreting Your Week-4 Lipid Panel

Use this three-question framework to interpret a week-4 result with your prescriber:

1. Did LDL fall by at least 50 percent from the pre-treatment baseline? If not, confirm the patient is injecting correctly, that the device is stored properly (not frozen or exposed to heat above 77 degrees F), and that the background statin dose has not changed.
2. Is the absolute LDL now below the guideline-recommended target for the patient's risk category? The 2018 ACC/AHA guideline and the 2022 ESC/EAS guideline both set <55 mg/dL as the target for very high cardiovascular risk [4, 13].
3. Are non-HDL cholesterol and apolipoprotein B also falling proportionally? FOURIER tracked apoB and showed a 49 percent reduction with evolocumab at week 12, consistent with the LDL reduction [7].

The FOURIER Outcome Data in Context

FOURIER enrolled 27,564 patients with established ASCVD on optimized statin therapy and randomized them to evolocumab or placebo [7]. At a median follow-up of 26 months, evolocumab reduced the composite primary endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15 percent (HR 0.85, 95 percent CI 0.79 to 0.92, P<0.001). The key secondary endpoint (cardiovascular death, MI, or stroke) fell by 20 percent (HR 0.80, 95 percent CI 0.73 to 0.88, P<0.001). These are absolute risk reductions of 1.5 and 1.0 percentage points, respectively, over a median 26 months. Dr. Marc Sabatine, the FOURIER lead investigator, stated in the NEJM publication: "The greater the reduction in LDL cholesterol, the greater the reduction in cardiovascular events, with no evidence of any floor effect" [7].

What a Non-Response Looks Like

A genuine non-response, defined as <30 percent LDL reduction, occurs in fewer than 5 percent of patients and may reflect injection technique errors, cold-chain failure, or rare anti-drug antibody formation [5]. Anti-evolocumab antibodies developed in 0.3 percent of patients in the phase 3 program, and none of these were neutralizing antibodies [5].

Managing Side Effects Across the First Month

Most tolerability issues with evolocumab appear within the first two weeks and do not worsen over time.

Injection-Site Care

Apply a cold pack to the injection site for 60 seconds before injecting to reduce stinging. After the injection, press gently with a clean gauze pad for 10 seconds without rubbing. Do not massage the site, as this may cause more bruising and could theoretically alter absorption kinetics, though no clinical data confirm the latter concern.

Flu-Like Symptoms

Nasopharyngitis and upper respiratory symptoms occurred in 11.3 percent of evolocumab-treated patients vs. 10.7 percent of placebo patients in FOURIER [7]. The difference is not statistically meaningful. If flu-like symptoms appear in week 1, they are almost certainly coincidental.

Diabetes Risk

Unlike statins, evolocumab has not been associated with an increased risk of new-onset diabetes. The FOURIER trial showed identical new-onset diabetes rates between evolocumab and placebo arms (8.1 percent vs. 8.0 percent) [7]. The American Diabetes Association standards of care note that PCSK9 inhibitors do not carry a diabetes signal [14].

Liver Enzyme Monitoring

Routine ALT/AST monitoring is not required by the evolocumab prescribing information, unlike some other lipid-lowering agents [5]. Clinically meaningful hepatotoxicity has not been observed in the phase 3 program. This absence of required liver monitoring distinguishes evolocumab from older agents like niacin.

Special Populations in the First Month

Familial Hypercholesterolemia Patients

Patients with HeFH typically see the largest absolute LDL drops because their baseline values are highest. The RUTHERFORD-2 trial (N=329), published in the Lancet in 2015, showed that evolocumab 140 mg Q2W reduced LDL by 59.2 percent from baseline in HeFH patients at week 12 [15]. The ACC/AHA 2018 guideline gives evolocumab a Class I, Level A recommendation for patients with HeFH whose LDL remains above 100 mg/dL on maximally tolerated statin therapy [4].

Patients with HoFH

Homozygous FH patients have severely impaired or absent LDL receptor activity, which blunts evolocumab's effect. The TESLA Part B trial (N=50) showed a mean LDL reduction of only 30.9 percent in HoFH vs. 59 to 66 percent in non-HoFH populations [16]. HoFH patients should have genotypic confirmation and be managed in conjunction with a lipid specialist, as some may require LDL apheresis alongside evolocumab.

Statin-Intolerant Patients

The GAUSS-3 trial (N=491) enrolled patients with statin intolerance and compared evolocumab 420 mg monthly to ezetimibe 10 mg daily [17]. Evolocumab produced a 52.8 percent LDL reduction vs. 16.7 percent for ezetimibe (P<0.001), with muscle symptom rates not significantly different from placebo. This trial supports evolocumab as a viable primary lipid-lowering option when statins cannot be tolerated.

When to Contact Your Prescriber During the First Month

Call your prescriber or seek urgent care if you experience any of the following during month 1:

• Hives, swelling of the face or throat, or difficulty breathing within hours of injection (possible allergic reaction).
• Severe muscle pain or weakness accompanied by dark urine (possible rhabdomyolysis, though this is not causally linked to evolocumab in trials).
• Injection-site redness that spreads, feels warm, or is accompanied by fever (possible infection).
• Any new neurological symptom such as memory loss or confusion lasting more than 24 hours (report for documentation, though EBBINGHAUS showed no causal link).

The FDA MedWatch program accepts voluntary reports of adverse events at fda.gov/medwatch [18].

What Months 2 Through 6 Look Like After the First Month

The first month is primarily about tolerability. Month 2 onward is about sustained cardiovascular risk reduction.

In FOURIER, cardiovascular event reduction became statistically significant at approximately 6 months of follow-up and continued to diverge through 26 months [7]. The longer patients remain on therapy, the greater the absolute event reduction, which is consistent with the hypothesis that sustained low LDL allows gradual plaque stabilization. A 2022 open-label extension of FOURIER (FOURIER-OLE, N=6,635) published in Circulation confirmed that longer duration of evolocumab use was associated with further reductions in MI and stroke risk, with no new safety signals emerging over a median of 5 years [19].

Expect your prescriber to recheck a fasting lipid panel at 8 to 12 weeks, then annually if targets are met. The 2022 ESC/EAS dyslipidaemia guideline recommends checking lipids 8 weeks after any therapy change to confirm target attainment [13].